


Amendments to the Claims:

1. **(Currently Amended)** A method of treating a subject for a sleep disorder, comprising administering to a subject in need of treatment for a sleeping disorder an effective amount of a compound represented by structural formula **II**[[;]]:





wherein

[[R¹]]R₁ and [[R²]]R₂ independently are -H, halogen, hydroxy, -CN, -NO₂, C₁₋₆-alkyl, halogenated C₁₋₆-alkyl, C₁₋₆-alkoxy, halogenated C₁₋₆-alkoxy, -NR²¹R²², -(SO₂)NR²¹R²², -NR²¹(SO₂)NR²², -(CO)NR²¹R²², -NR²¹(CO)R²², -(CO)R²², or -(CO₂)R²²[[,]];

R²¹ and R²² independently are -H or C₁₋₆-alkyl;

R₀ is C₁₋₆-alkyl, halogenated C₁₋₆-alkyl, C₁₋₆-alkoxy, halogenated C₁₋₆-alkoxy, phenyl, phenyl substituted with halogen, hydroxy, nitro or cyano, -(CH₂)_qCOR^p, -(CH₂)_qCONHSO₂Aryl, -(CH₂)_qCONHSO₂Heteroaryl, -(CH₂)_qCONHS(O)₂-Alkyl, -(CH₂)_qOH, -(CH₂)_qSO₂R^p, -(CH₂)_qS(O)₂NHCO-alkyl, -(CH₂)_qS(O)₂NHCO-aryl, -(CH₂)_qS(O)NHCO-alkyl,

-(CH₂)_qS(O)NHCO-aryl, -(CH₂)_qP(O)(OH)₂, -(CH₂)_qP(O)OH, -(CH₂)_q , or



wherein q is 0, 1 or 2;


R^p is H, OH or C₁₋₈ alkyl[[,]];


r is 1, 2, 3 or 4;

m is 1 or 2[[,]];

t is 1, 2, or 3; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

2. **(Original)** The method of Claim 1 wherein the subject is a human.
3. **(Original)** The method of Claim 1, wherein the subject is treated for a circadian rhythm adjustment disorder.
4. **(Original)** The method of Claim 1, wherein the subject is treated for a sleep disorder selected from sleep apnea, somnambulism, night terrors, restless leg syndrome, sleep onset insomnia, and sleep maintenance insomnia.
5. **(Original)** The method of Claim 4 wherein the subject is treated for sleep onset insomnia or sleep maintenance insomnia.
6. **(Currently Amended)** A method of treating a subject for a sleep disorder, comprising administering to a subject in need of treatment for a sleeping disorder an effective amount of a compound represented by structural formula **IIIa** or **IIIb**:






wherein

$[[R^1]]R_1$ and $[[R^2]]R_2$ independently are -H, halogen, hydroxy, -CN, -NO₂, C₁₋₆-alkyl, halogenated C₁₋₆-alkyl, C₁₋₆-alkoxy, halogenated C₁₋₆-alkoxy, -NR²¹R²², -(SO₂)NR²¹R²², -NR²¹(SO₂)NR²², -(CO)NR²¹R²², -NR²¹(CO)R²², -(CO)R²², or -(CO₂)R²², and R²¹ and R²² independently are -H or C₁₋₆-alkyl;

R_x and R_y are, independently, hydrogen, C₁₋₆-alkyl, halogenated C₁₋₆-alkyl, C₁₋₆-alkoxy, halogenated C₁₋₆-alkoxy, or, taken together, R_x and R_y form a bond;

T is COOH, COOR^a, CONHSO₂Aryl, CONHSO₂Heteroaryl, CONHS(O)₂Alkyl, SO₃H, S(O)₂NHCOAlkyl, S(O)₂NHCOAryl, S(O)NHCOAlkyl, (O)NHCO-Aryl, P(O)(OH)₂,



R^a is C₁-C₆ alkyl;



q is 0, 1 or 2;

r is 1, 2, 3 or 4; and

m is 1 or 2; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

7. **(Original)** The method of Claim 6 wherein the subject is a human.
8. **(Original)** The method of Claim 6, wherein the subject is treated for a circadian rhythm adjustment disorder.


9. **(Original)** The method of Claim 6, wherein the subject is treated for a sleep disorder selected from sleep apnea, somnambulism, night terrors, restless leg syndrome, sleep onset insomnia, and sleep maintenance insomnia.
10. **(Original)** The method of Claim 9 wherein the subject is treated for sleep onset insomnia or sleep maintenance insomnia.
11. **(Currently Amended)** A method of treating a subject for a sleep disorder, comprising administering to a subject in need of treatment for a sleeping disorder an effective amount of a compound represented by structural formula **IVa** or **IVb**:



wherein

$[[R^1]]R_1$ and $[[R^2]]R_2$ independently are -H, halogen, hydroxy, -CN, -NO₂, C₁₋₆-alkyl, halogenated C₁₋₆-alkyl, C₁₋₆-alkoxy, halogenated C₁₋₆-alkoxy, -NR²¹R²², -(SO₂)NR²¹R²², -NR²¹(SO₂)NR²², -(CO)NR²¹R²², -NR²¹(CO)R²², -(CO)R²², or -(CO₂)R²², and R²¹ and R²² independently are -H or C₁₋₆-alkyl;

T is COOH, COOR^a, CONHSO₂Aryl, CONHSO₂Heteroaryl, CONHS(O)₂Alkyl, SO₃H, S(O)₂NHCOAlkyl, S(O)₂NHCOAryl, S(O)NHCOAlkyl, S(O)NHCO-Aryl, P(O)(OH)₂,





R^a is C₁-C₆ alkyl;

q is 0, 1 or 2; and

r is 1, 2, 3 or 4; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

12. **(Original)** The method of Claim 11 wherein the subject is a human.
13. **(Original)** The method of Claim 11, wherein the subject is treated for a circadian rhythm adjustment disorder.
14. **(Original)** The method of Claim 11, wherein the subject is treated for a sleep disorder selected from sleep apnea, somnambulism, night terrors, restless leg syndrome, sleep onset insomnia, and sleep maintenance insomnia.
15. **(Original)** The method of Claim 14 wherein the subject is treated for sleep onset insomnia or sleep maintenance insomnia.
16. **(Currently Amended)** A method of treating a subject for a sleep disorder, comprising administering to a subject in need of treatment for a sleeping disorder an effective amount of a compound represented by structural formula **Va** or **Vb**:







wherein

$[[R^1]]R_1$ and $[[R^2]]R_2$ independently are -H, halogen, hydroxy, -CN, -NO₂, $[[o]]C_{1-6}$ -alkyl, halogenated C_{1-6} -alkyl, C_{1-6} -alkoxy, halogenated C_{1-6} -alkoxy, -NR²¹R²², -(SO₂)NR²¹R²², -NR²¹(SO₂)NR²², -(CO)NR²¹R²², -NR²¹(CO)R²², -(CO)R²², or -(CO₂)R²², R²¹ and R²² independently are -H or C_{1-6} -alkyl;


R^a is C_1 - C_6 alkyl; and

U is COOH, COOR^a, CONHSO₂Aryl, , or ; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

17. **(Original)** The method of Claim 16 wherein the subject is a human.
18. **(Original)** The method of Claim 16, wherein the subject is treated for a circadian rhythm adjustment disorder.
19. **(Original)** The method of Claim 16, wherein the subject is treated for a sleep disorder selected from sleep apnea, somnambulism, night terrors, restless leg syndrome, sleep onset insomnia, and sleep maintenance insomnia.
20. **(Original)** The method of Claim 19 wherein the subject is treated for sleep onset insomnia or sleep maintenance insomnia.
21. **(Original)** The method of Claim 1, 6, 11, or 16 wherein R¹ and R² independently are -H, halogen, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy.

22. (Original) The method of Claim 1, 6, 11, or 16, wherein R^1 and R^2 independently are -H or halogen.

23. (Original) A method of treating a subject for insomnia, comprising administering to a subject in need of treatment for insomnia an effective amount of a compound 1:



or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

24. (Original) The method of Claim 23, wherein the compound is the *R* isomer of compound 1.

25. (Original) The method of Claim 23, wherein the compound is the *S* isomer of compound 1.

26. (New) The method of Claim 23, 24 or 25 wherein the subject is a human.